AssetMark Inc
BMY.RT

AssetMark Inc’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

AssetMark Inc’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-22
Closed – – 1589
2020
Q4 		$0 Sell
22
-909
-98% -$1.94K ﹤0.01% 1524
2020
Q3 		$2K Sell
931
-354
-28% -$1.01K ﹤0.01% 1187
2020
Q2 		$5K Hold
1,285
– – ﹤0.01% 966
2020
Q1 		$5K Sell
1,285
-2,261
-64% -$7.45K ﹤0.01% 1101
2019
Q4 		$11K Buy
+3,546
New +$9.22K ﹤0.01% 1018

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

AssetMark Inc's BMY.RT Position: Q1 2021 in Review

AssetMark Inc sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 22 shares.

AssetMark Inc first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $11K in Q4 2019. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • AssetMark Inc reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • AssetMark Inc sold 22 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021.
  • AssetMark Inc first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • AssetMark Inc's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $11K in Q4 2019.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on AssetMark Inc's 13F filing for Q1 2021, filed 14 May 2021.